S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q4 2021

Baker Bros Advisors

Period: Q4 2021 Β· Filed: 2022-02-14
View on SEC EDGAR β†—
AUM
$20.55B
Total portfolio value
Positions
121
Reported securities
Top Holding
SGEN
35.3% $7.25B
QoQ Changes
+5 / -6
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2022-02-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$7.25B35.27%β€”β€”
35.3%
ONCBeiGene, Ltd.$3.16B15.38%$270.93$297.65+9.9%
15.4%
INCYIncyte Corporation$2.47B12.01%$73.40$116.86+59.2%
12.0%
KODKodiak Sciences Inc.$1.24B6.06%$84.78$38.54-54.5%
6.1%
ACADACADIA Pharmaceuticals Inc.$978.2M4.76%$23.34$25.97+11.3%
4.8%
BMRNBioMarin Pharmaceutical Inc.$673.3M3.28%$88.35$58.99-33.2%
3.3%
ASNDAscendis Pharma A/S$611.0M2.97%$134.53$274.50+104.0%
3.0%
ARGXargenx SE$392.1M1.91%$350.19$939.68+168.3%
1.9%
MRTXMirati Therapeutics, Inc.$206.8M1.01%β€”β€”
1.0%
BCRXBioCryst Pharmaceuticals, Inc.$176.0M0.86%$13.85$9.84-28.9%
0.9%
KYMRKymera Therapeutics, Inc.$151.4M0.74%$63.49$113.51+78.8%
0.7%
NVTAQInvitae Corporation$150.8M0.73%β€”β€”
0.7%
ABCLAbCellera Biologics Inc.$149.4M0.73%$14.30$8.11-43.3%
0.7%
MDGLMadrigal Pharmaceuticals, Inc.$127.0M0.62%$84.74$528.10+523.2%
0.6%
PRLDPrelude Therapeutics Inc.$126.0M0.61%$12.45$4.91-60.6%
0.6%
LEGNLegend Biotech Corporation$116.0M0.56%$46.61$29.91-35.8%
0.6%
PACBPacific Biosciences of California, Inc.$111.4M0.54%$20.46$1.68-91.8%
0.5%
GBTGlobal Blood Therapeutics, Inc.$97.0M0.47%β€”β€”
0.5%
CERSCerus Corporation$93.4M0.45%$6.81$3.16-53.6%
0.5%
IGMSIGM Biosciences, Inc.$92.6M0.45%β€”β€”
0.5%
IMCRImmunocore Holdings plc$86.3M0.42%$34.24$32.50-5.1%
0.4%
TVTXTravere Therapeutics, Inc.$82.8M0.40%$31.04$56.92+83.4%
0.4%
TRDAEntrada Therapeutics, Inc.$80.5M0.39%$17.12$7.72-54.9%
0.4%
HRTXHeron Therapeutics, Inc.$74.2M0.36%$9.13$0.44-95.2%
0.4%
AMRNXXXXAmarin Corporation plc$71.3M0.35%β€”β€”
0.3%
NRIXNurix Therapeutics, Inc.$71.0M0.35%$28.95$23.97-17.2%
0.3%
TILInstil Bio, Inc.$66.6M0.32%$342.20$7.73-97.7%
0.3%
MRUSMerus N.V.$64.8M0.32%β€”β€”
0.3%
HZNPHorizon Therapeutics Public Ltd Co$64.6M0.31%β€”β€”
0.3%
IMTXImmatics N.V.$59.5M0.29%$13.44$9.95-26.0%
0.3%

Quarter-on-Quarter Activity

Q4 2021 vs. Q3 2021

New Positions (5)

TickerIssuerNotionalSince Filing
TRDAEntrada Therapeutics, Inc.$80.5M-54.9%
TSVT2seventy bio, Inc.$21.4M
SRPTSarepta Therapeutics, Inc.$11.1M
FGENFibroGen, Inc.$8.2M
FHTXFoghorn Therapeutics Inc.$1.0M

Exited Positions (6)

TickerIssuerNotional
MIRMMirum Pharmaceuticals, Inc.$12.9M
AUPHAurinia Pharmaceuticals Inc.$11.5M
AMYTAmryt Pharma plc$6.2M
BioMarin Pharmaceutical Inc.$4.6M
XLRNAcceleron Pharma Inc.$3.9M
MREOMereo BioPharma Group plc$0.7M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
AFMDAffimed N.V.$13.6M+1511.8%
CCXIChemoCentryx, Inc.$54.2M+441.6%
TCRRTCR2 Therapeutics Inc.$2.0M+326.8%
REPLReplimune Group, Inc.$11.5M+286.5%
RLMDRelmada Therapeutics, Inc.$5.9M+146.3%
KRYSKrystal Biotech, Inc.$24.8M+32.9%
TVTXTravere Therapeutics, Inc.$33.4M+30.9%+83.4%
TCDAQTricida, Inc.$7.5M+23.9%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
ALBOAlbireo Pharma, Inc.$-10.4M-74.7%
Tricida, Inc.$-16.6M-63.3%
NVAXNovavax, Inc.$-15.7M-55.7%
FLGTFulgent Genetics, Inc.$-15.8M-49.8%
Apellis Pharmaceuticals, Inc.$-9.3M-32.1%
CRNXCrinetics Pharmaceuticals, Inc.$4.1M-10.1%
OPTEYOpthea Limited$-3.0M-5.5%
AMRNXXXXAmarin Corporation plc$-40.1M-3.1%
← Back to Hedge Funds